<DOC>
	<DOCNO>NCT01241422</DOCNO>
	<brief_summary>The purpose study evaluate allergen-induced late asthmatic response ( LAR ) , measure maximal percent fall force expiratory volume 1 second , participant stable mild atopic asthma treatment JNJ 40929837 compare placebo .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness JNJ 40929837 Treatment Asthma Using Bronchial Allergen Challenge Model</brief_title>
	<detailed_description>This multicenter ( study conduct multiple site ) , randomize ( study medication assign chance ) , double-blind ( neither physician participant know treatment participant receiving , access information case emergency ) , crossover ( method use switch participant one treatment arm another clinical study ) study . Approximately 18 participant participate study . The study consist screen phase ( 30 day administration study drug ) , treatment phase , follow-up phase ( 2 week end last treatment period ) . Participants randomly assign receive JNJ 40929837 , placebo , montelukast . Each participant receive 3 treatment ( 7 day per treatment ) treatment separate 14 day wash-out period ( treatment ) . Safety evaluation include assessment adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination , evaluate throughout study . The maximum study duration participant approximately 51 day .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Generally healthy Have mild atopic asthma require treatment besides occasional shortacting beta2agonists Have allergeninduced early asthmatic response least 20 percent reduction force expiratory volume 1 second ( FEV1 ) late asthmatic response least 15 percent reduction FEV1 bronchial allergen challenge perform screen Females post menopausal , surgically sterilize , practice highly effective method birth control Have FEV1 screen visit least 75 percent predict value Have history asthma symptom exposure indoor outdoor allergen positive prick skin test do study site dust mite , mixed grass pollen , cat dander Worsening asthma respiratory tract infection within 6 week HIV Hepatitis B C positive Receipt investigational drug use investigational medical device within last month Use tobacco product kind currently within 6 month Have clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram screening deem appropriate investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Mild asthma</keyword>
	<keyword>Singulair</keyword>
	<keyword>JNJ 40929837</keyword>
	<keyword>Montelukast</keyword>
</DOC>